OCUL
$8.18-0.09 (-1.09%)
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The...
Recent News
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
March 20 () - EyePoint filed a lawsuit on Friday accusing rival Ocular Therapeutix of spreading false or ‌misleading information about EyePoint and its lead experimental ‌eye drug. The complaint was filed in Middlesex County Superior Court for the ​Commonwealth of Massachusetts.
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.
Is It Time To Reassess Ocular Therapeutix (OCUL) After Its Recent Share Price Slide
If you are wondering whether Ocular Therapeutix at around US$8.68 is a bargain or a value trap, the key is understanding what the current price actually implies. The stock is down 12.1% over the last week and 2.3% over the last month, while still showing a 16.5% return over 1 year and 69.2% over 3 years, set against a 26.6% decline year to date and a 53.3% decline over 5 years. Recent attention on Ocular Therapeutix has centered on its position within the US pharmaceuticals and biotech...
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
Shareholders of Ocular Therapeutix would probably like to forget the past six months even happened. The stock dropped 29.1% and now trades at $8.62. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.